含替吉奥联合化疗方案在进展期胃癌治疗中的应用探讨  

Application experience of S-1 combined with chemotherapy in treatment of progressive stomach cancer

作　　者：徐向东[1] 张龙[1] 瞿凯泉 

机构地区：[1]启东市人民医院消化科,江苏启东226200

出　　处：《中外医疗》2016年第14期152-153,156,共3页China & Foreign Medical Treatment

摘　　要：目的探讨在进展期患者治疗中应用替吉奥与化学药物紫杉醇进行联合治疗的临床疗效。方法方便选取2012年9月—2015年9月期间该院收治的110例进展期胃癌患者在接受化学药物紫杉醇进行静脉输液治疗的基础上,将患者随机分组给予替吉奥胶囊与卡培他滨连续治疗21 d,随访统计患者1年存活率以及用药不良反应情况。结果研究组近期疗效及存活率(76.36%、76.36%)均显著高于对照组(36.36%、50.91%),但发生不良反应情况与对照组差异无统计学意义(P>0.05)。结论联合应用替吉奥与紫杉醇对进展期胃癌患者进行治疗,可短时间内控制患者病情发展,提高患者存活时间,效果比较显著。Objective To observe the clinical curative effect of the combined treatment of S-1 and chemical drug of paclitaxel for patients at the progressive stage. Methods 110 cases of patients with progressive stomach cancer admitted and treated in our hospital from September 2012 to September 2015 were selected and divided into two groups, both groups were given the intravenous infusion of paclitaxel, and the control group took capecitabine additionally for continuous 21 d, the research group took S-1 capsules additionally for continuous 21 d, and the 1-year survival rate and side reaction of the adverse drug use of patients were counted through follow-up. Results The short-term curative effect and survival rate in the research group were obviously higher than those in the control group, [（76.36%, 76.36%） vs（36.36%, 50.91%）], but there was no obvious difference in the occurrence of the adverse reactions between the two groups without statistical significance,P〉0.05. Conclusion S-1 combined with paclitaxel in treatment of patients with progressive stomach cancer can control the development of the disease condition in a short time and prolong the survival time of patients, and the effect is obvious.

关 键 词：进展期胃癌 替吉奥 化疗 

分 类 号：R735[医药卫生—肿瘤]